[email protected]/(408) 457-3700

About SYNG Pharmaceuticals Inc

SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the abnormal proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. SYNG Pharma is also developing its unique target protein into a biomarker and a rapid, non-invasive diagnostic for endometriosis to address an unmet need. There are many other potential applications for our technology including the treatment of prostate and uterine sarcoma; which may be further developed depending upon corporate interest. Immediate goals are to capitalize on ground breaking intellectual properties in developing diagnostic accompanied therapeutics for major unmet needs through pre-clinical research and Phase I /II clinical trials and enhance value of the asset/company for an appropriate exit.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Biotechnology, Diagnostics
Therapeutic Areas:
Ob / Gyn